{"id":33001,"date":"2025-07-02T16:18:11","date_gmt":"2025-07-02T16:18:11","guid":{"rendered":"https:\/\/www.europesays.com\/us\/33001\/"},"modified":"2025-07-02T16:18:11","modified_gmt":"2025-07-02T16:18:11","slug":"humira-market-size-hit-usd-1-20-billion-by-2032-growing-at-a-cagr-of-17-6-from-2024-to-2032","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/33001\/","title":{"rendered":"Humira Market Size Hit USD 1.20 Billion by 2032, Growing at a CAGR of -17.6% from 2024 to 2032"},"content":{"rendered":"

<\/p>\n

According to a latest report by
\nCoherent Market Insights, the global Humira Market<\/a> is projected to be valued
\nat USD 4.68 Bn in 2025, but is expected to decline to USD 1.20 Bn by 2032,
\nexperiencing a negative compound annual growth rate (CAGR) of -17.6% from 2025
\nto 2032. The Humira market is projected to undergo a substantial decline over
\nthe forecast period. This downward trend is primarily driven by growing
\ncompetition from biosimilars, following the expiration of Humira’s patent
\nprotection in several key markets. Furthermore, the emergence of innovative
\ntherapies addressing the same indications is intensifying this contraction. As
\nhealthcare systems increasingly prioritize cost-effective treatment options,
\nthe uptake of biosimilars and newer alternatives is expected to rise, further
\neroding Humira’s market share and dampening its growth outlook.<\/p>\n

Request Sample Report:<\/b> https:\/\/www.coherentmarketinsights.com\/insight\/request-sample\/8100<\/a> <\/p>\n

<\/b><\/b><\/p>\n

Global Humira Market Key Takeaways<\/p>\n

According to Coherent Market Insights
\n(CMI), the global Humira market size is
\nestimated to reach USD 4.68 Bn in 2025. However, due to widespread biosimilar
\nadoption, the market value is set to decline to USD 1.20 Bn by 2032,
\nexperiencing a CAGR of -17.6%.<\/p>\n

Based on indication, rheumatoid
\narthritis (RA) segment is expected to account for more than one-fourth of the global Humira market share in 2025.<\/p>\n

By gender, male category is projected
\nto hold a prominent market share of 54.2% in 2025.<\/p>\n

Prefilled syringe segment is
\nanticipated to account for over 4\/5 of the global Humira industry share in 2025.<\/p>\n

North America is expected to retain
\nits dominance, holding a market share of 37.3% in 2025.<\/p>\n

As per CMI\u2019s new Humira market analysis, Asia Pacific is
\nanticipated to record fastest growth over the assessment period.<\/p>\n

Get Instant Access! Purchase Research Report and Receive a 25% Discount: <\/b>https:\/\/www.coherentmarketinsights.com\/insight\/buy-now\/8100<\/a> <\/b><\/p>\n

Rising Incidence of Autoimmune Diseases
\nFueling Market Growth<\/b><\/p>\n

Coherent Market Insights\u2019 latest Humira market research report provides
\ninsights into key factors driving industry growth. One such prominent growth
\ndriver is the rising prevalence of autoimmune diseases.<\/p>\n

According to a study published by the
\nGlobal Autoimmune Institute, autoimmune diseases affect between 5% and 10% of
\nthe population in industrialized nations. This surge in autoimmune diseases
\nlike rheumatoid arthritis and psoriasis is driving demand for Humira.<\/p>\n

Humira is often used for the treatment
\nof autoimmune
\nand inflammatory conditions like rheumatoid arthritis, psoriatic arthritis,
\nCrohn’s disease, and ulcerative colitis. Therefore, increasing incidence of
\nthese diseases is a primary growth driver for the Humira industry.<\/p>\n

Also Read: <\/b>Humira Biosimilar Market
\nSize, Share, Trends & Opportunities for 2025-2032<\/b><\/a><\/p>\n

Biosimilar Competition and Newer
\nBiologics Restraining Market Growth<\/b><\/p>\n

The future Humira market outlook appears increasingly challenging. This is
\nmostly due to rising adoption of biosimilars and novel biologics.<\/p>\n

Humira\u2019s patent protections have
\nexpired across nations like the United States (2023). This is leading to entry
\nof cost-effective biosimilars like Amjevita and Cyltezo, thereby reducing
\noverall Humira market demand. <\/p>\n

Many physicians and patients are
\nincreasingly opting for next-generation treatments like Tremfya and Skyrizi due
\nto their safety profiles and greater efficacy. Shift towards these newer
\nbiologics will also negatively impact the Humira
\nmarket growth.<\/p>\n

Get
\nCustomization on this Report: <\/b>https:\/\/www.coherentmarketinsights.com\/insight\/request-customization\/8100<\/a> <\/b><\/p>\n

Emerging Humira Market Trends<\/b><\/p>\n

Humira has received multiple FDA and international approvals
\nfor a range of indications, including rheumatoid arthritis, psoriasis, and
\nCrohn\u2019s disease. This broad therapeutic versatility continues to drive demand
\nand may support market growth in specific regions, especially where biosimilar
\ncompetition is limited or delayed.<\/p>\n

Rising adoption of biologic therapies is also contributing to
\nthe expansion of Humira market. Healthcare professionals and patients are
\nincreasingly turning to biologics like Humira to manage chronic autoimmune
\ndiseases. However, the Humira market is also undergoing transformation due to
\nthe introduction of biosimilars, which may impact its growth trajectory across
\ndifferent regions.<\/p>\n

Also Read: <\/b>Autoimmune Disease
\nTreatment Market Analysis and Forecast for 2025-2032<\/b><\/a><\/p>\n

Analyst\u2019s View<\/b><\/p>\n

\u201cDespite positive initial figures, the global Humira
\nmarket value is expected to decline during the assessment period due to the
\nwidespread adoption of biosimilars and novel biologics,\u201d <\/b>said senior analyst Vipul Patil.<\/b><\/p>\n

Current Events and Their Impact on the Humira
\nMarket<\/b><\/p>\n\n\n

Event<\/b><\/p>\n<\/td>\n\n

Description
\n and Impact<\/b><\/p>\n<\/td>\n<\/tr>\n\n\n

Patent Expiration and Biosimilar Competition<\/b><\/p>\n<\/td>\n\n